23 research outputs found

    An explainable model of host genetic interactions linked to COVID-19 severity

    Get PDF
    We employed a multifaceted computational strategy to identify the genetic factors contributing to increased risk of severe COVID-19 infection from a Whole Exome Sequencing (WES) dataset of a cohort of 2000 Italian patients. We coupled a stratified k-fold screening, to rank variants more associated with severity, with the training of multiple supervised classifiers, to predict severity based on screened features. Feature importance analysis from tree-based models allowed us to identify 16 variants with the highest support which, together with age and gender covariates, were found to be most predictive of COVID-19 severity. When tested on a follow-up cohort, our ensemble of models predicted severity with high accuracy (ACC = 81.88%; AUCROC = 96%; MCC = 61.55%). Our model recapitulated a vast literature of emerging molecular mechanisms and genetic factors linked to COVID-19 response and extends previous landmark Genome-Wide Association Studies (GWAS). It revealed a network of interplaying genetic signatures converging on established immune system and inflammatory processes linked to viral infection response. It also identified additional processes cross-talking with immune pathways, such as GPCR signaling, which might offer additional opportunities for therapeutic intervention and patient stratification. Publicly available PheWAS datasets revealed that several variants were significantly associated with phenotypic traits such as "Respiratory or thoracic disease", supporting their link with COVID-19 severity outcome.A multifaceted computational strategy identifies 16 genetic variants contributing to increased risk of severe COVID-19 infection from a Whole Exome Sequencing dataset of a cohort of Italian patients

    The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males

    Get PDF
    The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFι production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-ι: tumor necrosis factor

    Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19

    Get PDF
    Thrombosis of small and large vessels is reported as a key player in COVID-19 severity. However, host genetic determinants of this susceptibility are still unclear. Congenital Thrombotic Thrombocytopenic Purpura is a severe autosomal recessive disorder characterized by uncleaved ultra-large vWF and thrombotic microangiopathy, frequently triggered by infections. Carriers are reported to be asymptomatic. Exome analysis of about 3000 SARS-CoV-2 infected subjects of different severities, belonging to the GEN-COVID cohort, revealed the specific role of vWF cleaving enzyme ADAMTS13 (A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 13). We report here that ultra-rare variants in a heterozygous state lead to a rare form of COVID-19 characterized by hyper-inflammation signs, which segregates in families as an autosomal dominant disorder conditioned by SARS-CoV-2 infection, sex, and age. This has clinical relevance due to the availability of drugs such as Caplacizumab, which inhibits vWF-platelet interaction, and Crizanlizumab, which, by inhibiting P-selectin binding to its ligands, prevents leukocyte recruitment and platelet aggregation at the site of vascular damage

    Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes

    Get PDF
    Carriers of single pathogenic variants of the CFTR (cystic fibrosis transmembrane conductance regulator) gene have a higher risk of severe COVID-19 and 14-day death. The machine learning post-Mendelian model pinpointed CFTR as a bidirectional modulator of COVID-19 outcomes. Here, we demonstrate that the rare complex allele [G576V;R668C] is associated with a milder disease via a gain-of-function mechanism. Conversely, CFTR ultra-rare alleles with reduced function are associated with disease severity either alone (dominant disorder) or with another hypomorphic allele in the second chromosome (recessive disorder) with a global residual CFTR activity between 50 to 91%. Furthermore, we characterized novel CFTR complex alleles, including [A238V;F508del], [R74W;D1270N;V201M], [I1027T;F508del], [I506V;D1168G], and simple alleles, including R347C, F1052V, Y625N, I328V, K68E, A309D, A252T, G542*, V562I, R1066H, I506V, I807M, which lead to a reduced CFTR function and thus, to more severe COVID-19. In conclusion, CFTR genetic analysis is an important tool in identifying patients at risk of severe COVID-19

    Could Temperamental Features Modulate Participation in Clinical Trials?

    No full text
    The prodromal stages of Alzheimer’s disease (AD) are the primary focus of research aimed at slowing disease progression. This study explores the influence of affective temperament on the motivation of people with mild cognitive impairment (MCI) and subjective cognitive decline (SCD) to participate in clinical trials. One hundred four subjects with MCI and SCD were screened for participation in pharmacological and non-pharmacological trials. Affective temperament was assessed based on the Temperament Evaluation of the Memphis, Pisa, Paris and San Diego (TEMPS) scale. Demographic variables and temperament subscales scores were compared between MCI and SCD patients and among patients participating in the pharmacological trial, the non-pharmacological trial and refusing participation. Twenty-one subjects consented to participate in the pharmacological trial, seventy consented to the non-pharmacological trial and thirteen refused to participate in any trial. Patients with SCD had greater education and more depressive temperamental traits than those with MCI. While older age, higher education and anxious temperament were negatively associated with participation in the pharmacological trial, irritable temperamental positively predicted pharmacological trial participation. In conclusion, temperamental features may affect the willingness of patients with MCI and SCD to take part in clinical trials and, especially, the choice to participate in pharmacological studies

    Dysgraphia as a Mild Expression of Dystonia in Children with Absence Epilepsy

    Get PDF
    <div><p>Background</p><p>Absence epilepsy (AE) is etiologically heterogeneous and has at times been associated with idiopathic dystonia.</p><p>Objectives</p><p>Based on the clinical observation that children with AE often exhibit, interictally, a disorder resembling writer’s cramp but fully definable as dysgraphia, we tested the hypothesis that in this particular population dysgraphia would represent a subtle expression of dystonia.</p><p>Methods</p><p>We ascertained the prevalence of dysgraphia in 82 children with AE (mean age 9.7) and average intelligence and compared them with 89 age-, gender- and class-matched healthy children (mean age 10.57) using tests for handwriting fluency and quality, based on which we divided patients and controls into four subgroups: AE/dysgraphia, AE without dysgraphia, controls with dysgraphia and healthy controls. We compared the blink reflex recovery cycle in children belonging to all four subgroups.</p><p>Results</p><p>We identified dysgraphia in 17/82 children with AE and in 7/89 controls (20.7 vs 7.8%; P = 0.016) with the former having a 3.4-times higher risk of dysgraphia regardless of age and gender (odd ratio: 3.49; 95% CI 1.2, 8.8%). The AE/dysgraphia subgroup performed worse than controls with dysgraphia in one test of handwriting fluency (P = 0.037) and in most trials testing handwriting quality (P< 0.02). In children with AE/dysgraphia the blink reflex showed no suppression at short interstimulus intervals, with a difference for each value emerging when comparing the study group with the three remaining subgroups (P<0.001).</p><p>Conclusions</p><p>In children with AE, dysgraphia is highly prevalent and has a homogeneous, distinctive pathophysiological substrate consistent with idiopathic dystonia.</p></div

    Handwriting performance.

    No full text
    <p>(A) Patient 12. Example of handwriting during “uno “(above) and “le” (below) test. The child performed slowly. (B) Patient 9. Example of handwriting performance during ‘best’ (above) and ‘faster’ (below) conditions. We considered this patient’s performance as inadequate.</p

    R2 blink reflex recovery cycle.

    No full text
    <p>Children with absence epilepsy/dysgraphia showed higher R2 values, compared to the three remaining groups. <b>(Lower part)</b> Blink reflex in a healthy control (A) and in a child with absence epilepsy/dysgraphia, showing no R2 suppression (B), which resolved at follow-up (C).</p

    La Depressione nell'Adulto con Disturbo dello Spettro Autistico ad alto funzionamento: Prevalenza, Fattori di Rischio, e Trattamenti: una revisione sistematica

    No full text
    Questo studio esplora la connessione tra il Disturbo dello Spettro Autistico (ASD) di livello 1 in assenza di disabilità cognitiva e la depressione negli adulti. Gli adulti con ASD hanno un rischio 4 volte maggiore rispetto alla popolazione generale di sviluppare depressione, a causa di fattori come deficit nella Teoria della Mente, isolamento sociale, disturbi del sonno e ideazione suicidaria. Mentre alcune terapie cognitivo-comportamentali e quella basata sulla mindfulness possono aiutare, le sfide diagnostiche e la sensibilità ai farmaci complicano la gestione. L'obiettivo di questa revisione sistematica è (1) valutare in che misura è diffusa la sintomatologia depressiva tra gli adulti con autismo ad alto funzionamento e (2) identificare i fattori di rischio e protettivi specifici associati allo sviluppo della depressione negli adulti con autismo ad alto funzionamento. Metodi: Questa revisione sistematica, in linea con le linee guida PRISMA, ha analizzato la comorbilità della depressione negli adulti con autismo ad alto funzionamento; alla fine della revisione sono stati inclusi 18 articoli nell’analisi. Discussioni: Gli adulti con Disturbo dello Spettro Autistico (ASD) hanno un alto rischio di depressione. La depressione può essere influenzata dai tratti autistici, complicando il quadro. Alcuni fattori di rischio includono le difficoltà nelle funzioni esecutive, problemi di Teoria della Mente e riconoscimento facciale, isolamento sociale e difficoltà sociali, disturbi del sonno e un rischio aumentato di suicidio. Sono necessarie ulteriori ricerche per comprendere i fattori protettivi e i trattamenti efficaci per la depressione in individui con ASD
    corecore